Anthem Inc., the second largest U.S. health insurer, has agreed to lift coverage barriers to getting naloxone and other prescription drugs as part of treatment for opioid addiction, New York Attorney General Eric T. Schneiderman (D) announced Jan. 19.
In a letter to Anthem, Schneiderman said that by Jan. 30 the insurer will end its requirement that patients get prior authorization for oral medications, including buprenorphine and a buprenorphine-naloxone combination used to treat opioid-use disorder.
Also, Anthem affiliate Empire Blue Cross Blue Shield will end prior authorization requirements for injectable naltrexone in its New York service area. ...
Learn more about Bloomberg Law or Log In to keep reading:
See Breaking News in Context
Bloomberg Law provides trusted coverage of current events enhanced with legal analysis.
Already a subscriber?
Log in to keep reading or access research tools and resources.